Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer

Adriana Rossi, MD Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning. In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.    DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode:  Minimal/Measurable Residual Disease Minimal/Measurable Residual Disease Chart  Tests (FISH, Flow Cytometry, Next-generation Sequencing) The Revolution of Genomics: How Testing Leads to Individualized Treatment Multiple Myeloma Acute Lymphoblastic Leukemia Additional LLS Support Resources:  Information Specialists  Financial support Free telephone/web patient programs  Free booklets  Clinical Trial Support Center Young Adult Resources Caregiver support  Caregiver Workbook Survivorship Workbook Online chats  LLS Community  Support groups  Patti Robinson Kaufmann First Connection Program  Free Nutrition Consultations Support for this episode provided by: Adaptive BiotechnologiesThe post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline with Blood Cancer United Podcast.